Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical
benefits, including anti-anxiety and antidepressant properties. This study is a pilot
open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4
weeks in patients with bipolar disorder who experience anxiety.